Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era

Shannon Wood,1,2,3 Seung Hyun Won,3,4 Hsing-Chuan Hsieh,3,4 Tahaniyat Lalani,3,4,5 Karl Kronmann,3,6 Ryan C. Maves,7 Gregory Utz,7 Christina Schofield,3,5 Rhonda E. Colombo,3,4 Jason F. Okulicz,3 Jason Blaylock,2,3 Brian K. Agan,3,4,6 and Anuradha Ganesan2,3

1Department of Internal Medicine, Madigan Army Medical Center, Tacoma, Washington, USA, 2Division of Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, Maryland, USA, 3Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA, 4The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA, 5Division of Infectious Diseases, Madigan Army Medical Center, Tacoma, Washington, USA, 6Division of Infectious Diseases, Naval Medical Center Portsmouth, Portsmouth, Virginia, USA, and 7Division of Infectious Diseases, Naval Medical Center San Diego, San Diego, California, USA.

Open Forum Infectious Diseases®2021

Background. As morbidity due to viral coinfections declines among HIV-infected persons, changes in liver-related morbidity are anticipated. We examined data from the US Military HIV Natural History Study (NHS), a cohort of military beneficiaries, to evaluate incidence and risk factors associated with chronic liver enzyme elevation (cLEE) in HIV-monoinfected patients in the combination antiretroviral therapy (cART) era.

Methods. Participants who were hepatitis B virus and hepatitis C virus seronegative with follow-up after 1996 were included. We defined chronic liver enzyme elevation (cLEE) as alanine aminotransferase elevations ≥1.25 times the upper limit of normal on at least 2 visits, for a duration of ≥6 months within 2 years. We used multivariate Cox proportional hazards models to examine risk factors for cLEE.

Results. Of 2779 participants, 309 (11%) met criteria for cLEE for an incidence of 1.28/100 PYFU (1.28–1.29/100 PYFU). In an adjusted model, cLEE was associated with Hispanic/other ethnicity (reference Caucasian: hazard ratio [HR], 1.744; 95% CI, 1.270–2.395), non–nucleoside reverse transcriptase inhibitor–based cART (reference boosted protease inhibitors: HR, 2.232; 95% CI, 1.378–3.616), being cART naïve (HR, 6.046; 95% CI, 3.686–9.915), or having cART interruptions (HR, 8.671; 95% CI, 4.651–16.164). African American race (HR, 0.669; 95% CI, 0.510–0.877) and integrase strand transfer inhibitor (INSTI)–based cART (HR, 0.222; 95% CI, 0.104–0.474) were protective.

Conclusions. Our findings demonstrate that initiation and continued use of cART are protective against cLEE and support the hypothesis that HIV infection directly impacts the liver. INSTI-based regimens were protective and could be considered in persons with cLEE.

Keywords. ALT; ART; chronic liver enzyme elevation; hepatitis; HIV.

Combination antiretroviral therapy (cART) has transformed the lives of people with HIV (PWH), with life expectancy nearing that of the general population [1]. However, morbidity and mortality due to non-AIDS-related conditions continue [2, 3], with liver disease remaining a major contributor [2, 4, 5].

Even in the absence of hepatitis B (HBV) or hepatitis C (HCV) coinfection, abnormal liver-associated enzymes (LAEs) are common in PWH, occurring in 40%–60% of persons on ART [6]. Viral hepatitis, excessive alcohol use, ART toxicity, and nonalcoholic fatty liver disease (NAFLD) can contribute to LAE abnormalities in PWH [7]. However, in clinical practice, the underlying cause of LAE elevations and the clinical significance are often difficult to discern, especially when elevations are mild [8] and hepatitis coinfections are absent.

While occasional mild to moderate LAE elevations may not alarm most practitioners, these abnormalities may be relevant. Alanine aminotransferase (ALT) abnormalities in HIV-monoinfected subjects are infrequently investigated (23% in 1 study, with only 6% undergoing assessment for hepatic fibrosis) [9]. However, high rates of histologic abnormalities, largely nonalcoholic steatohepatitis (NASH), were found in PWH with unexplained chronic transaminase elevations [10]. Furthermore, ALT has been associated with death from liver disease in persons without HBV and HCV [11].

Received 23 November 2020; editorial decision 9 February 2021; accepted 19 February 2021.
Correspondence: Shannon Wood, MD, MPH, Madigan Army Medical Center, Department of Internal Medicine, 9040 Jackson Ave, Tacoma, WA 98431 (shannon.m.wood22.mil@mail.mil).

Open Forum Infectious Diseases®2021
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/ofid/ofab076
Historically, research on LAE elevations in PWH has focused on coinfection with HBV/HCV or extreme LAE elevations [6]. Few studies have examined the significance of modest elevations in LAEs in persons without viral hepatitis coinfections in the era of modern cART.

The goals of our study were to evaluate trends in ALT abnormalities, determine the incidence of chronic liver enzyme elevation (cLEE), and identify risk factors associated with cLEE in a large cohort of PWH without HBV or HCV coinfection. We also evaluated the association between cLEE and long-term outcomes.

**METHODS**

**Study Population**
The US Military HIV Natural History Study (NHS) is an ongoing, longitudinal, prospective observational cohort started in 1986 and comprised of US active duty military and Department of Defense (DoD) beneficiaries with HIV [12]. Study visits occur about once every 6 months. Participants undergo physical examination and coordinator interview, answer questionnaires, have medical records abstracted for clinical diagnosis, and have blood drawn for clinically relevant parameters including liver function tests.

For this analysis, participants were included if they contributed at least 6 months of follow-up between 1996 and 2017, did not have active HBV and/or HCV, and had normal alanine aminotransferase (ALT) at baseline (ie, at HIV diagnosis).

**Patient Consent Statement**
All participants provided written informed consent. This study was approved by the Institutional Review Board (IRB) of the Uniformed Services University of the Health Sciences (USU) and participating study sites.

**Definitions**
Serum ALT is a marker of potential liver injury and was used in our analysis as a surrogate marker of liver disease [7, 11]. Abnormal ALT was defined as \( \geq 1.25 \times \) the upper limit of normal (Grade 1 or higher), in accordance with NIH-NIAI guidelines [13]. Chronic liver enzyme elevation (cLEE) was defined as an abnormal ALT recorded on at least 2 visits, with intervals between elevations totaling at least 6 months within 2 years. This allowed for intermittent normal values between intervals of elevation. We grouped cART regimens based on the following anchor classes: unboosted protease inhibitor (PI), boosted PI, non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase strand transfer inhibitor (INSTI), and other combinations. We defined treatment interruption as discontinuing treatment for \( \geq 6 \) months.

We defined HBV infection as a positive hepatitis B surface antigen or detectable HBV DNA at any point. We did not exclude subjects with isolated positive hepatitis B core antibody or resolved infection (ie, core and surface antibody positive). We required a positive HCV antibody or detectable HCV RNA at any point for a diagnosis of hepatitis C. Participants with resolved hepatitis C were not included.

For this study, trained clinical research coordinators perform chart reviews to capture and record protocol-specified diagnoses in the NHS database. We categorized participants as having hyperlipidemia if they had a diagnosis recorded in the NHS database or a low-density lipoprotein cholesterol (LDL) value \( \geq 190 \) mg/dL. Hypertension and cirrhosis were based on the capture of a clinical diagnosis. We defined diabetes mellitus (DM) based on a recorded diagnosis, the use of antidiabetic medications, or laboratory findings suggestive of DM (ie, fasting blood glucose levels \( >126 \) mg/dL, random blood glucose \( >200 \) mg/dL or hgbA1C \( \geq 6.5 \), on 2 or more determinations). At-risk drinking was defined as the consumption of at least 3 or 4 drinks per day or 7 and 14 drinks per week among women and men, respectively, using criteria established by the National Institute for Alcohol Abuse and Alcoholism (NIAAA) [14].

Two indirect markers of liver fibrosis were utilized in our analyses, the aspartate transaminase (AST) to platelet ratio index (APRI) and the fibrosis-4 index (FIB-4). While traditionally used for predicting fibrosis in patients with HCV or HIV/HCV coinfection, the APRI may also be useful for predicting NAFLD fibrosis [15]. The FIB-4 index was developed to stage liver disease in persons with HIV/HCV coinfection, although it has been found to be superior to other noninvasive markers in the setting of NALFD [16, 17].

**Statistical Analyses**
Incidence of cLEE was defined as the number of patients with cLEE divided by the total number of person-years of follow-up time (PYFU). Characteristics between patients with and without cLEE were compared using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Medians and interquartile ranges (IQRs) are presented unless stated otherwise. We censored participants with cLEE at the time they first met criteria for cLEE and censored those without cLEE at their last visit. We analyzed the time to first event.

Risk factors for cLEE included demographics (eg, age, race) and HIV-specific factors (eg, CD4 count, viral load, and cART regimens). Age, CD4 count, and viral load were considered time-dependent covariates. Unadjusted and adjusted hazards ratios are reported with 95% CIs and \( P \) values. Risk factors significant in the univariate logistic model (listed in Table 1) were evaluated in unadjusted Cox models. Factors significant at a \( P \) value <.05 in the unadjusted Cox model were selected for evaluation in an adjusted Cox model. We took collinearity into consideration in model construction.
As older versions of the study had not required it, body mass index (BMI), hypertension, DM, and hyperlipidemia were not consistently captured until 2006; hence we conducted sensitivity analyses restricted to participants with BMI at HIV diagnosis and participants diagnosed with HIV after 2006 to examine the effects of these risk factors.

Additionally, due to the established hepatotoxicity associated with older antiretrovirals [4, 8, 18], we also performed a sensitivity analysis grouping participants into the following treatment categories: treatment naïve; treatment containing stavudine (D4T), didanosine (ddI), or zalcitabine (ddC), hereafter referred to as “D-drugs”; and all other treatments. As treatment is recommended universally, to better define the role of cART use and cLEE, we also analyzed data beginning at cART initiation and treated cART as a time-updated variable. All statistical analyses were performed using SAS, version 9.3 (SAS Institute, Inc., Cary, NC, USA).

**RESULTS**

**Subject Characteristics**

Overall, 2779 participants without HBV or HCV coinfection who had normal baseline ALT were included (Figure 1). The study population largely consisted of younger men (93%; 27.7 [23.7–33.7] years) and was racially diverse, with African American [AA] and Hispanic/other comprising 45% and 15% of the population, respectively. Most participants were diagnosed with HIV

### Table 1. Pertinent Participant Characteristics Categorized by the Presence or Absence of Chronic Liver Enzyme Elevation

| Variable                                      | All Participants | Chronic Liver Enzyme Elevation | P     |
|-----------------------------------------------|------------------|--------------------------------|-------|
|                                               | n = 2779         | No                             | Yes   |       |
| Sex                                           |                  |                                |       |       |
| Male                                          | 2580 (92.8)      | 2289 (92.7)                    | 291 (94.2) | .3342 |
| Ethnicity/race                                |                  |                                |       |       |
| Caucasian                                     | 1092 (39.3)      | 961 (38.9)                     | 131 (42.4) | .0005 |
| African American                              | 1260 (45.3)      | 1148 (46.5)                    | 112 (36.2) |       |
| Hispanic/other                                | 427 (15.4)       | 361 (14.6)                     | 66 (21.4) |       |
| Age at HIV diagnosis, y                       | 27.7 [23.7–33.7] | 27.6 [23.5–33.5]               | 29.2 [25.0–35.3] | .0012 |
| Year of HIV diagnosis                         |                  |                                |       |       |
| Before 1996                                   | 907 (32.6)       | 755 (30.6)                     | 152 (49.2) | <.0001 |
| 1996–2000                                     | 350 (12.6)       | 306 (12.4)                     | 44 (14.2) | <.0001 |
| 2001–current                                  | 1522 (54.8)      | 1409 (57.0)                    | 113 (36.6) | <.0001 |
| Age at cART initiation, y                     | 31.5 [26.2–38.1] | 31.0 [25.8–37.8]               | 34.2 [29.0–40.0] | <.0001 |
| Year of cART initiation                       |                  |                                |       | <.0001 |
| Before 1996                                   | 8 (0.3)          | 5 (0.2)                        | 3 (1.0) | <.0001 |
| 1996–2000                                     | 895 (38.0)       | 730 (35.4)                     | 165 (56.9) | <.0001 |
| 2001–current                                  | 1459 (62.0)      | 1334 (64.4)                    | 125 (43.1) | <.0001 |
| Time from HIV diagnosis to cART initiation, y | 1.1 [0.2–4.8]    | 1.0 [0.2–4.5]                  | 3.4 [0.5–7.0] | <.0001 |
| Hepatitis B status                            |                  |                                |       | <.0001 |
| No HBV                                       | 1927 (69.34)     | 1749 (70.81)                   | 178 (57.61) | <.0001 |
| Resolved HBV                                  | 797 (28.68)      | 670 (27.13)                    | 127 (41.10) | <.0001 |
| Isolated hep B core                          | 55 (1.98)        | 51 (2.06)                      | 4 (1.29) | <.0001 |
| CD4 count at HIV diagnosis, cells/μL²         | 483.0 [350.0–635.0] | 488.0 [354.0–638.0] | 440.0 [327.0–594.0] | .0114 |
| CD4 count at cART initiation, cells/μL²      | 366.0 [257.0–495.0] | 371.0 [264.0–509.0] | 319.0 [193.0–436.0] | <.0001 |
| Nadir CD4 count, cells/μL                    | 302.0 [199.0–420.0] | 311.0 [211.0–430.0] | 236.0 [130.0–329.0] | <.0001 |
| AIDS diagnosis before cART¹                  | 119 (5.0)        | 92 (4.4)                       | 27 (9.2) | .0005 |
| HIV RNA level at cART initiation, log10 copies/mL³ | 4.5 [3.9–5.0] | 4.5 [3.9–5.0] | 4.5 [3.9–5.0] | .8067 |
| Peak HIV RNA level, log10 copies/mL³         | 4.8 [4.3–5.2]    | 4.8 [4.3–5.1]                  | 4.9 [4.5–5.4] | <.0001 |
| First ART treatment                          |                  |                                |       | <.0001 |
| ART naïve                                     | 264 (9.5)        | 260 (10.5)                     | 4 (1.3) | <.0001 |
| ART-containing D-drugs                        | 233 (8.4)        | 199 (8.1)                      | 34 (11.0) | <.0001 |
| All other ART                                 | 2282 (82.1)      | 2011 (81.4)                    | 271 (87.7) | <.0001 |
| First cART²                                   |                  |                                |       | <.0001 |
| Unboosted PI                                  | 812 (34.4)       | 664 (32.1)                     | 148 (50.5) | <.0001 |
| Boosted PI                                    | 198 (8.4)        | 183 (8.8)                      | 15 (5.1) | <.0001 |
| NNRTI                                        | 970 (41.1)       | 858 (41.5)                     | 112 (38.2) | <.0001 |
| INSTI                                         | 325 (13.8)       | 318 (15.4)                     | 7 (2.4) | <.0001 |
and initiated cART after the year 2000: 55% and 62%, respectively. The median CD4 count at HIV diagnosis (IQR) was 483 (350–635) cells/μL, and the median nadir CD4 count (IQR) was 302 (199–420) cells/μL. The median time from HIV diagnosis to initiation of cART (IQR) was 1.1 (0.2–4.8) years. Most participants initiated treatments without “D-drugs” (82%), with NNRTI-based regimens being the most common cART (41%). Efavirenz was the most common anchor NNRTI drug. Of the 138 participants with cLEE and exposure to an NNRTI before the onset of cLEE, 119 (86%) had received efavirenz, 19 (14%) nevirapine, and 9 (6.5%) rilpivirine. The prevalence of hypertension, hyperlipidemia, and DM during the study period was 26%, 41%, and 10%, respectively, with 19% of the population ever on a statin. Most participants (65%) reported some alcohol use, with 7% meeting criteria for alcohol abuse. Nonprescription drug abuse was reported by 5% of participants (Table 1).

Comparisons of Participants With and Without cLEE

Participants with cLEE differed from those without cLEE in several aspects, notably ethnicity/race and age (Table 1). Participants with cLEE were more likely to be Caucasian (42.4% vs 38.9%) or Hispanic/other (21.4% vs 14.6%) and were older at both HIV diagnosis (29.2 vs 27.6 years) and
cART initiation (34.2 vs 31.0 years) compared with participants without cLEE. They were more often diagnosed with HIV before the year 2000 (63.4% vs 43%) and, in keeping with this, had a longer time to cART initiation from HIV diagnosis (3.4 vs 1.0 years) and were more likely to initiate treatment with “D-drugs” (11% vs 8.1%) or unboosted PIs (50.5% vs 32.1%). Hypertension (42% vs 24%), hyperlipidemia (70% vs 37%), statin use (40% vs 17%), DM (28% vs 7%), resolved hepatitis B infection (41% vs 27%), and alcohol abuse (10.4% vs 7.1%) were more common in participants with cLEE.

Participants with cLEE were overall less likely to be antiretroviral naïve (1.3% vs 10.5%) and cART naïve (5.2% vs 16.2%). However, 16.8% of participants with cLEE did not initiate any antiretroviral until after meeting criteria for cLEE. Similarly, of the 293 participants with cLEE who received cART, 109 (37%) did not initiate cART until after meeting criteria for cLEE. For this analysis, those with and without cLEE were followed for a median (IQR) of 4.8 (2.3–7.7) years and 6.8 (3.2–12.4) years, respectively.

**Incidence of cLEE and ALT Trends**

A total of 65,867 ALT measurements were analyzed, and 1180 participants (42%) had at least 1 abnormal ALT value during follow-up, for an incidence of 6.88 per 100 PY (95% CI, 6.87–6.89), and 309 (11%) met the definition of cLEE, with an incidence of 1.28 per 100 PY (95% CI, 1.28–1.29). The median number of months between ALT measures was ~5 months and was different between those with and without cLEE at 1.6 and 5.6 months, respectively.

In general, transient elevations in ALT were common (42.4%, n = 1180) and grade 1 ALT abnormalities predominated (66%); however, among those with cLEE (n = 309), the majority had ALT abnormalities that were grade ≥2 at some point in time (56%, n = 172) (Figure 2). While 18% of the participants (n = 137) with grade 1 ALT elevations at some point (n = 730) met criteria for cLEE, this proportion was 43% (n = 173) in those with grade 2 elevations (n = 400) (Figure 3). ALT fluctuations were common, and a majority with cLEE (n = 276, 89%) reverted to normal. Most participants reverting to normal (57%, n = 158) were on the same cART regimen both at cLEE diagnosis and when they reverted. Only 12% (n = 32) who were cART naïve at cLEE diagnosis had initiated cART when they reverted. The remaining switched regimens between the 2 time points, either the anchor drug or the nucleoside backbone.

**Risk Factors Associated With cLEE**

In the adjusted model, risk factors for cLEE included Hispanic/other ethnicity (reference Caucasian: HR, 1.744; 95% CI, 1.270–2.395), NNRTI-based cART (HR, 2.232; 95% CI, 1.378–3.616), cART-naïve status (HR, 6.046; 95% CI, 3.686–9.915), and cART interruption (HR, 8.671; 95% CI, 4.651–16.164). AA race (reference Caucasian: HR, 0.669; 95% CI, 0.510–0.877) and INSTI-based cART were protective (HR, 0.222; 95% CI, 0.104–0.474; P = .0001) (Table 2).

In a sensitivity analysis evaluating 1353 participants with BMI values at HIV diagnosis, higher BMI was a risk factor for cLEE, although the sample size for the analysis was nearly halved due to missing values (Supplementary Tables 1). BMI at cART did not show this association (data not shown). As anticipated,
Table 2. Factors Associated With Chronic Liver Enzyme Elevation

| Variable                        | Unadjusted Hazard Ratios | Adjusted Hazard Ratios |
|---------------------------------|---------------------------|------------------------|
|                                 | HR (95% CI)              | P Value                | HR (95% CI)         | P Value                |
| Ethnicity/race                  |                           |                        |                      |                        |
| Caucasian Reference             | Reference                 |                        | Reference           |                        |
| African American                | 0.696 (0.532–0.910)       | .0081                  | 0.669 (0.510–0.877) | .0036                  |
| Hispanic/other                  | 1.652 (1.204–2.266)       | .0019                  | 1.744 (1.270–2.395) | .0006                  |
| Age at time T (per 10 y)*       | 0.938 (0.802–1.098)       | .4250                  |                        |                        |
| Year of HIV diagnosis           |                           |                        |                      |                        |
| Before 1996 Reference           | Reference                 |                        | Reference           |                        |
| 1996–2000                       | 1.281 (0.904–1.184)       | .1633                  |                        |                        |
| 2000–current                    | 1.148 (0.876–1.506)       | .3176                  |                        |                        |
| CD4 count at time T (per 100 cells/μL)* | 0.959 (0.918–1.003) | .0680                  |                        |                        |
| HIV RNA viral load at time T (log10 copies/mL)* | 1.036 (0.941–1.140) | .4696                  |                        |                        |
| Year of cART initiation         |                           |                        |                      |                        |
| 1996–2000 Reference             | Reference                 |                        | Reference           |                        |
| 2000–current                    | 0.897 (0.699–1.151)       | .3922                  |                        |                        |
| Rx at cLEE*                     |                           |                        |                      |                        |
| Boosted PI Reference            | Reference                 |                        | Reference           |                        |
| Unboosted PI                    | 1.568 (0.859–2.862)       | .1433                  | 1.651 (0.904–3.017) | .1030                  |
| NNRTI                           | 2.253 (1.391–3.650)       | .0010                  | 2.232 (1.378–3.616) | .0011                  |
| INSTI                           | 0.221 (0.103–0.472)       | <.0001                 | 0.222 (0.104–0.474) | .0001                  |
| Other cART                      | 0.572 (0.273–1.196)       | .1374                  | 0.569 (0.272–1.191) | .1345                  |
| cART naive*                     | 5.550 (3.391–9.082)       | <.0001                 | 6.046 (3.686–9.915) | <.0001                 |
| cART interruption              | 9.745 (5.238–18.129)      | <.0001                 | 8.671 (4.651–16.164) | <.0001                 |
| APRI ≥0.7 before cLEE           | 1.258 (0.989–1.601)       | .0615                  |                        |                        |

n = 2730, with 273 participants with cLEE.

Abbreviations: APRI, aspartate transaminase to platelet ratio index; cART, combination antiretroviral therapy; cLEE, chronic liver enzyme elevation; HR, hazard ratio; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Rx, treatment.

*Time-updated variable.

Data for participants without cLEE were obtained from the last visit.

Includes participants who did not initiate cART until after cLEE/last visit.

Figure 3. Proportion of participants with abnormal ALT (n = 1180) who met criteria for cLEE based on their highest ALT elevation by grade. Abbreviations: ALT, alanine aminotransferase; cLEE, chronic liver enzyme elevation.
“D-drug” use was associated with cLEE (Supplementary Table 2). A protective association with INSTI use was also observed in analyses restricting the data to time points after cART initiation and treating cART use as a time updated variable (Supplementary Table 3) as well as among participants diagnosed with HIV after 2006 (Supplementary Table 4).

Outcomes

Cirrhosis occurred in only 9 participants (0.3%). Rates of documented cardiovascular disease, cardiomyopathy, congestive heart failure, and peripheral arterial disease were similarly low, occurring in <1% of the population. Participants with cLEE were more likely to develop cirrhosis (1.6% vs 0.2%) and have a diagnosis of coronary artery disease without MI (5.8% vs 2.0%) than those without cLEE.

Elevations of indirect markers of liver fibrosis were common among NHS participants. APRI calculations ≥0.7 and FIB-4 >1.45 were observed in 40.2% and 41.7% of participants, respectively. Participants with cLEE were more likely to have APRI ≥0.7 (76.4% vs 35.6%) and FIB-4 >1.45 (63.4% vs 38.9%) (Table 3). About a quarter of the patients with cLEE had a FIB4 >3.25, and ~40% had an APRI >1.5, indicative of progression to advanced fibrosis (Table 3).

DISCUSSION

Even in the absence of hepatitis coinfections, ALT abnormalities were frequent in this cohort, with nearly half (42%) the participants exhibiting at least 1 abnormal ALT. However, these elevations were often transient and did not persist; only 1 in 10 participants met the criteria for cLEE, for an overall incidence of 1.2 per 100 PYFU. Most ALT abnormalities in our cohort were grade 1 or 2, with only 5% demonstrating grade ≥3 elevations. While lower-grade ALT elevations typically garner less attention, our results indicate that nearly 1 in 5 participants with transient grade 1 ALT elevations will progress to cLEE, and this fraction is significantly higher in those with grade 2 elevations (42%). Future studies should examine if PWH with transient grade ≥2 ALT elevations will benefit from noninvasive monitoring and risk stratification to determine the extent of hepatic fibrosis in addition to serial monitoring of LAEs.

The incidence of cLEE observed in the NHS is lower than reported in other studies, which may be a reflection of a younger cohort with a lower proportion of treatment-naive participants. Higher incidences of cLEE have been reported in cohorts of older participants, such as the Swiss HIV Cohort study (incidence of 3.9 cases/100 PYFU, median age at HIV diagnosis of 38 years, compared with 28 years in the NHS) [8]. Another retrospective series reported an incidence of 5.8 per 100 PYFU of cLEE, and again participants were older (median age, 40 years) and had a lower nadir CD4 count (147 cells/μL vs 302 cells/μL) [19]. Furthermore, this study’s definition of cLEE was less stringent when compared with ours (ALT greater than the upper limit of normal at 2 consecutive visits 3–12 months apart) [19], likely contributing to the higher incidence reported.

The association between HIV-specific parameters and LAE elevations remains unclear. Several studies have identified associations between elevated HIV RNA levels in HIV-monoinfected participants and markers of liver damage [8, 20] or indirect markers of liver fibrosis [21–23], supporting the hypothesis that HIV infection directly influences liver injury. In our study, CD4 count and HIV RNA levels were not significant; however, the absence of treatment and treatment interruptions had the largest effect sizes for predicting cLEE, supporting the hypothesis that HIV infection may be directly impacting LAE abnormalities.

The only identified risk factor for cLEE not related to treatment was an individual’s race/ethnicity. While Hispanic/other ethnicity was associated with cLEE, AA race was protective. The Swiss HIV Cohort study similarly identified African origin as inversely related to cLEE [8]. Overall, we hypothesize...
that the differences in cLEE risk according to race may reflect differences in propensity for NAFLD or hepatic steatosis. In the general population, Hispanics are more likely and AA less likely to have hepatic steatosis compared with Caucasians [24]. Similarly, studies in PWH have demonstrated that AAs are less likely to have NAFLD and severe fibrosis compared with Caucasians [25, 26].

As previously noted, the most significant risk factors for cLEE were lack of cART, either because participants were cART naïve or had interrupted treatment, underscoring the importance of initiating and remaining on cART to prevent cLEE. The hepatotoxic potential of D-drugs [4, 8, 18] and NNRTIs has been previously established and was also observed in this study [27–29]. The effects of the NNRTIs may not be a class effect and could be dictated by the specific drug used; in fact, the hepatotoxic potential of nevirapine is very well recognized [29]. In our study, the majority of participants with cLEE were receiving efavirenz; hence, we did not have adequate power to study the effect of the newer members of this class, such as rilpivirine.

Of particular interest was the protective association observed with INSTI-based cART. This protective association was observed in both the overall analysis where cART use at the time of cLEE was examined and in a sensitivity analysis in which cART use was treated as a time-updated variable beginning at cART initiation. Taramasso et al. similarly found protective associations with INSTI regimens in a cohort containing both HIV/hepatitis-coinfected and HIV-monoinfected participants [30]. Overall, these findings suggest that modern cART may be protective against liver injury. These findings also suggest that INSTI-based regimens could be considered in persons with LAE elevations. However, these medications are relatively new, and long-term outcome data as they relate to LAE abnormalities are limited. Additionally, weight gain has been associated with use of dolutegravir [31], and weight gain in adults is a significant risk factor for NAFLD [32]. Ongoing investigation into the long-term impact of INSTI-based regimens on liver function is warranted.

Features of metabolic syndrome, including hypertension, hyperlipidemia, and DM, were more common in those with cLEE, despite these data not being reliably available for participants diagnosed before 2006. In the subgroup analysis evaluating only patients diagnosed with HIV after 2006, hyperlipidemia was more common in participants with cLEE; however, it was not significant in the multivariate model, likely a reflection of the low numbers of events. As in other retrospective studies, establishing a causal link between conditions associated with metabolic syndrome and cLEE is challenging [33].

Clinically diagnosed cirrhosis was uncommon; nevertheless, elevations in APRI and/or FIB-4 were common overall (about 1 in 3) and occurred more frequently in participants with cLEE (3 in 4). The clinical significance of this finding is unclear; however, an elevated FIB-4 score has been independently associated with liver fibrosis in HIV-monoinfected persons [34]. In fact, nearly half the participants with cLEE had evidence of advanced fibrosis (based on an APRI >1.5 or FIB-4 >3.25), which suggests that this group should be the focus of interventions and monitoring strategies designed to impede and reverse fibrosis.

Our study has several limitations. First, ALT levels were used as a surrogate marker of liver disease rather than more definitive methods such as imaging, but we did observe an association with cLEE and advanced fibrosis based on noninvasive measures. Alcohol use is common in this population [35], but the impact of alcohol or statins on cLEE could not be completely assessed, as data were not routinely solicited before 2006. We tried to overcome some of these limitations by performing an analysis restricted to those diagnosed with HIV after 2006, but the small number of outcomes limited our ability to detect any associations with alcohol or statin use. Similarly, we could not specifically assess the role of metabolic syndrome on cLEE, as abdominal circumference was not captured. Neither could we assess the impact of nonalcoholic fatty liver disease and steatohepatitis on cLEE. Finally, there could be an ascertainment bias in play, as those with cLEE were more likely to have frequent ALT measurements.

While our cohort was large and diverse, it was comprised solely of DoD beneficiaries who have open access to care and medications. Additionally, active duty personnel are required to undergo biannual HIV testing, often aiding in the early diagnosis and initiation of treatment. As a consequence, the findings in this study may not necessarily reflect those of the general population.

The strengths of this study are the presence of long-term follow-up, the lack of significant confounders provided all participants have access to care and there is limited drug use, and the availability of granular ART and serial ALT information, allowing evaluation of the role of ART, especially modern cART, in cLEE.

In conclusion, transient and persistent ALT abnormalities are common in PWH, and cLEE was observed in 10% of this early diagnosed and treated population with open access to care and medications. The lack of ART and treatment interruptions had the largest effect size. Hence, consistent with clinical guidelines, ART should be initiated earlier rather than later, and INSTI-based cART may offer protective benefit against HIV-associated liver injury.

**Acknowledgments**

The authors are grateful to the participants of the US Military Natural History Study for their contributions to this study; without their support, this work would not have been possible; and to Morgan Byrne and William Bradley for their statistical contribution.
Financial support. Support for this work (IDCRP-000-03) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under InterAgency Agreement Y1-AI-5072 and from the Defense Health Program, US Department of Defense, under award HU0001190002.

Potential conflicts of interest. The authors have no conflicts of interest to disclose. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Disclaimer. The views expressed are those of the authors and do not reflect the official views of the Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the National Institutes of Health or the Department of Health and Human Services, Brooke Army Medical Center, Walter Reed National Military Medical Center, Naval Medical Center San Diego, Madigan Army Medical Center, Naval Medical Center Portsmouth, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of Defense, the Departments of the Army, Navy or Air Force, or the US Government. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense, or the US Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. The investigators have adhered to the policies for protection of human subjects as prescribed in 45CFR46.

Author contributions. We certify that all individuals who qualify as authors have been listed; each has participated in the conception and design of this work, the analysis of data (when applicable), the writing of the document, and the approval of the submission of this version; that the document represents valid work; that if we used information derived from another source, we obtained all necessary approvals to use it and made appropriate acknowledgements in the document; and that each takes public responsibility for it. Some authors on this paper are military service members and/or employees of the US Government. As such, this work was prepared as part of official duties. Title 17 U.S.C. 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person’s official duties.

Prior presentation. This work was presented in part at the Annual Infectious Disease Society of America Meeting; October 4–8, 2017; San Diego, CA (Abstract 597).

References
1. Samji H, Cescon A, Hogg RS, et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IDeA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.
2. Pellela PJ Jr, Baker RK, Moorman AC, et al. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006; 43:27–34.
3. Bruguera M, Morelli E, Cattelan F, et al. Non-AIDS defining malignancies among human immunodeficiency virus-positive subjects: epidemiology and outcome after two decades of HAART era. World J Virol 2015; 4:209–18.
4. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8:1002–12.
5. Oikonomou KG, Tsai E, Sarpel D, Dieterich DT. Liver disease in human immunodeficiency virus infection. Clin Liver Dis 2019; 23:309–29.
6. Girlsaid R, Boyer JL, Schilder K, Nixen D, Thomas AR, Zier B. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008; 53:1375–82.
7. Cai J, Osikowicz M, Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients. AIDS 2019; 33:1267–82.
8. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50:502–11.
9. Shur NF, Tan Y, Goubet S, et al. Non-viral liver disease burden in HIV-monoinfected individuals: a longitudinal observational retrospective cohort study. AIDS Care 2016; 28:1522–7.
10. Ingiliz P, Valantin MA, Duvier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436–42.
11. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136:477–85.e11.
12. Agan BK, Ganasan A, Byrne M, et al; Infectious Disease Clinical Research Program HIV Working Group. The US Military HIV Natural History Study: informing military HIV care and policy for over 30 years. Mil Med 2019; 184:16–17.
13. Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis 2015; 19:1–22.
14. Davis RG, Mesner O, Agan BK, et al. Characterizing the association between alcohol and HIV virologic failure in a military cohort on antiretroviral therapy. Alcohol Clin Exp Res 2014; 40:529–35.
15. Angulo P, Bugianesi E, Bjoronsen ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145:782–9:4.
16. Shah AG, Lydecker A, Murray K, et al; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104–12.
17. Sterling RK, Lissen E, Chumack N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317–25.
18. Brinkman K, ter Hofste DJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735–44.
19. Alghamdi S, Alrbiaan A, Alaraj A, et al. Elevated alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection. Ann Saudi Med 2016; 36:288–91.
20. Mata-Marín JA, Gaytán-Martínez J, Grados-Chavarría BH, et al. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naïve patients: a concordance cross-sectional study. Virol J 2009; 6:181.
21. Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4 – a noninvasive index of liver fibrosis – in women. Clin Infect Dis 2011; 52:674–80.
22. Forrester JE, Rhee MS, McGovern BH, et al. The association of HIV viral load with indirect markers of liver injury. J Viral Hepat 2012; 19:e202–11.
23. DallaPazza M, Amorosa VK, Locako R, et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10:116.
24. Browning JD, Szczepaniak LS, Dobkins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387–95.
25. Crum-Cianflone N, Dilaia A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:64–73.
26. Marks KM, Petrovic J, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192:1943–9.
27. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23:173–82.
28. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59:342–6.
29. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182–9.
30. Taramasso L, Lorenzini P, Di Biagio A, et al; ICONA Foundation Study Group. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother 2019; 74:3295–304.
31. Bourgi K, Jenkins CA, Rebeiro PF, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc 2020; 23:e25484.
32. Kimura T, Deshpande GA, Urayama KY, et al. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015; 30:909–17.
33. Rothman KI, Greenland S. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998.
34. Mohr R, Schierwagen R, Schwarze-Zander C, et al. Liver fibrosis in HIV patients receiving a modern cART: which factors play a role? Medicine (Baltimore) 2015; 94:e2127.
35. Byrne M, Deiss R, Mesner O, et al. Age, race, and at-risk drinking in an HIV-infected US military cohort. Mil Med 2019; 184:e263–7.